As of June 17, 2025, Intra-Cellular Therapies Inc (ITCI) reports a Forward P/E of 654.18.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Intra-Cellular Therapies Inc's Forward P/E to Peers
To better understand Intra-Cellular Therapies Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Intra-Cellular Therapies Inc (ITCI) | 654.18 |
| Catalent Inc (CTLT) | 55.81 |
| Eli Lilly and Co (LLY) | 36.62 |
| Zoetis Inc (ZTS) | 25.66 |
| Elanco Animal Health Inc (ELAN) | 16.28 |
| Johnson & Johnson (JNJ) | 14.48 |
Compared to its competitors, Intra-Cellular Therapies Inc's Forward P/E is higher than all peers, reflecting higher growth expectations from investors.